Allurion Technologies Inc. (ALUR) AI Stock Analysis

Allurion Technologies Inc. is dedicated to combatting obesity through its weight loss platform designed for individuals struggling with overweight conditions. Central to its offerings is the Allurion Program, which introduces the Allurion Balloon, a swallowable intragastric balloon providing a procedure-less approach to weight loss. The platform integrates AI-powered remote patient monitoring tools, a proprietary behavior change program, and secure messaging and video telehealth capabilities via the Allurion Virtual Care Suite. Headquartered in Natick, Massachusetts, the company focuses on advancing accessible, non-surgical solutions that combine medical innovation with personalized patient care.

Allurion's annual revenue rose to $64.2M in FY2022 before dropping across consecutive years to $53.5M in FY2023, $32.1M in FY2024, and $15.2M in FY2025, reflecting a 4-year revenue CAGR of -20.6%. Gross margin compressed from 79.0% in FY2022 to 62.8% in FY2025. Operating margin was -198.0% in FY2025, while net margin stood at -188.8% with a net loss of -$28.8M and an EPS of -$8.05. Over the trailing twelve months ended March 31, 2026, revenue was $12.6M, operating margin was -126.6%, and profit margin was -264.7%. In the quarter ended March 31, 2026, quarterly revenue fell 47.2% year-over-year, while quarterly earnings growth was 7119.4%.

As of March 31, 2026, Allurion held $5.1M in cash and short-term investments against total debt of $29.4M, resulting in net debt of $24.4M. Total assets stood at $14.0M, and shareholders' equity was negative at -$77.9M. The company reported a current ratio of 0.30. In FY2025, operating cash flow was -$28.9M and free cash flow was -$28.9M, while research and development expense was $7.6M. Over the 5-year period, the company's share count increased by 209.6%.

At a last close of $0.47 on October 16, 2026, Allurion had a market cap of $288,634 and an enterprise value of $25.5M. The stock trades at a forward P/E of 1.0x, a price-to-sales of 0.0x, and an EV-to-revenue multiple of 2.0x. For comparison, the median of its US-listed Healthcare peers trades at a forward P/E of 17.3x and a price-to-sales of 4.1x. Over the 1-year period, the stock fell 76.6%, while the S&P 500 (SPY) returned 16.8%. Over 5 years, the stock fell 99.8% compared to an 83.0% return for the S&P 500.

For the fiscal year ending December 31, 2026, the EPS estimate is -$20.25 and the revenue estimate is $0. For the next fiscal year, 1 analyst projects revenue of $85.0M and an EPS of -$1.24. The mean price target is $82.50, which stands 17268.4% above the last close of $0.47. Over the last 4 quarters, Allurion has beat EPS estimates 1 time.

This page is an AI-written research summary of Allurion Technologies Inc. (ALUR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ALUR income statement, ALUR balance sheet, ALUR key metrics, ALUR analyst forecast, ALUR chart. See the ALUR stock overview for the latest quote and news.